Artrya (ASX:AYA): SAPPHIRE partner Huntsville Hospital Health System signs 5 year commercial agreement; investor call Wednesday
Artrya announced on Friday that it had signed a five-year commercial agreement with SAPPHIRE partner Huntsville Hospital Health System. Huntsville...
86 Views
Artrya (ASX:AYA): Share price dragged down by EchoIQ FDA denial; AYA joins S&P/ASX 300; Scenario test the robustness of our forecasts maintain $6.07 per share valuation
Artrya fell -21% last week and at one point, was down another -8% today. At today’s close, the shares are down -50% from their all-time high of...
104 Views
Racura Oncology (ASX:RAC): One drug, three shots
Venn Brown sat down with Daniel Tillett, CEO of Racura Oncology, to discuss the three potential applications for RC220, their potential market...
111 Views
Artrya (ASX:AYA): Downgrade valuation, but market overraction represents buying opportunity
The market responded negatively to Artrya’s 4Q26 cash flows today, closing down -16%. While there was some frustration in the delay in realising...
154 Views
Artrya (ASX:AYA): Disappointing 4Q26 cash flow
Artrya released its 4Q26 cash flow report today. Overall, it was a disappointing read (shares closed down -6.3%), with cash receipts below...
248 Views